BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 34200676)

  • 1. Drugging the Undruggable: Advances on RAS Targeting in Cancer.
    Molina-Arcas M; Samani A; Downward J
    Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34200676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugging all RAS isoforms with one pocket.
    Kessler D; Bergner A; Böttcher J; Fischer G; Döbel S; Hinkel M; Müllauer B; Weiss-Puxbaum A; McConnell DB
    Future Med Chem; 2020 Nov; 12(21):1911-1923. PubMed ID: 32779487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugging K-Ras
    Ni D; Li X; He X; Zhang H; Zhang J; Lu S
    Pharmacol Ther; 2019 Oct; 202():1-17. PubMed ID: 31233765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAS-targeted therapies: is the undruggable drugged?
    Moore AR; Rosenberg SC; McCormick F; Malek S
    Nat Rev Drug Discov; 2020 Aug; 19(8):533-552. PubMed ID: 32528145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.
    Coley AB; Ward A; Keeton AB; Chen X; Maxuitenko Y; Prakash A; Li F; Foote JB; Buchsbaum DJ; Piazza GA
    Adv Cancer Res; 2022; 153():131-168. PubMed ID: 35101229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in cancer drug discovery targeting RAS.
    Wilson CY; Tolias P
    Drug Discov Today; 2016 Dec; 21(12):1915-1919. PubMed ID: 27506872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugging RAS: Know the enemy.
    Papke B; Der CJ
    Science; 2017 Mar; 355(6330):1158-1163. PubMed ID: 28302824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of RAS: proven and potential vulnerabilities.
    Zuberi M; Khan I; O'Bryan JP
    Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS
    Hoshiyama H
    Nihon Yakurigaku Zasshi; 2023; 158(5):391-398. PubMed ID: 37673617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Kras
    Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
    J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugging KRAS: current perspectives and state-of-art review.
    Parikh K; Banna G; Liu SV; Friedlaender A; Desai A; Subbiah V; Addeo A
    J Hematol Oncol; 2022 Oct; 15(1):152. PubMed ID: 36284306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors.
    Huynh MV; Campbell SL
    Mini Rev Med Chem; 2016; 16(5):383-90. PubMed ID: 26423694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological targeting of RAS: Recent success with direct inhibitors.
    O'Bryan JP
    Pharmacol Res; 2019 Jan; 139():503-511. PubMed ID: 30366101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging strategies to target RAS signaling in human cancer therapy.
    Chen K; Zhang Y; Qian L; Wang P
    J Hematol Oncol; 2021 Jul; 14(1):116. PubMed ID: 34301278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic targeting of RAS: New hope for drugging the "undruggable".
    Khan I; Rhett JM; O'Bryan JP
    Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118570. PubMed ID: 31678118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
    Roskoski R
    Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
    Nagasaka M; Li Y; Sukari A; Ou SI; Al-Hallak MN; Azmi AS
    Cancer Treat Rev; 2020 Mar; 84():101974. PubMed ID: 32014824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting mutated GTPase KRAS in tumor therapies.
    Fan G; Lou L; Song Z; Zhang X; Xiong XF
    Eur J Med Chem; 2021 Dec; 226():113816. PubMed ID: 34520956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
    Chen Y; Liu QP; Xie H; Ding J
    Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving Prospects for Targeting RAS.
    Singh H; Longo DL; Chabner BA
    J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.